Recent Updates
Recently added Catalysts
NVCR Negative Sentiment Score: 30/100

NOVOCURE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR

Key Takeaway: Kahn Swick & Foti, LLC has issued a reminder to investors regarding a class action lawsuit against NovoCure Limited, with a lead plaintiff application deadline of August 18, 2023. The lawsuit claims that NovoCure and its executives did not disclose material information during the class period, violating federal securities laws. Despite reporting positive results from its Phase 3 LUNAR trial for a lung cancer therapy, the stock saw a significant decline in value due to analysts' concerns about the treatment's applicability in standard care protocol. The action is currently pending in the Southern District of New York.

Market Sentiment Analysis

POSITIVE FACTORS

  • NovoCure announced positive results from the Phase 3 LUNAR clinical trial.
  • The Tumor Treating Fields therapy has potential applications in treating non-small cell lung cancer.

CONCERNS & RISKS

  • The company is involved in a class action lawsuit for failing to disclose material information.
  • Shares of NovoCure dropped 43.04% following the announcement of trial results.

Full Press Release Details

NEW ORLEANS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against NovoCure Limited (NasdaqGS: NVCR), if they purchased the Company’s securities between January 5, 2023 to June 5, 2023, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
If you purchased securities of NovoCure and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-nvcr/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 18, 2023.
NovoCure and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On June 6, 2023, the Company announced “positive results” from the Phase 3 LUNAR clinical trial evaluating the use of its Tumor Treating Fields therapy together with standard therapies for the treatment of non-small cell lung cancer; however, despite some positive aspects to the news, analysts noted that the therapy was tested in patients who worsened following chemotherapy, which is no longer the standard of care in lung cancer, and that most patients first receive immune checkpoint inhibitors.
On this news, shares of NovoCure fell $35.51 per share, or 43.04%, to close at $47.00 per share on June 6, 2023.
The case is Bazzelle v. NovoCure Limited, et al., No. 23-cv-5146.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.
To learn more about KSF, you may visit http://ksfcounsel.com/.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
1100 Poydras St., Suite 960
New Orleans, LA 70163

Tags

Frequently Asked Questions

What is the deadline to file lead plaintiff applications?

The deadline to file lead plaintiff applications is August 18, 2023.

What is the class action lawsuit related to?

It concerns NovoCure Limited for failing to disclose important information.

When did NovoCure's stock price drop significantly?

The stock dropped on June 6, 2023, by 43.04%.

Who can be contacted regarding this case?

Lewis Kahn can be contacted at 1-877-515-1850 or lewis.kahn@ksfcounsel.com.

What was announced on June 6, 2023, by NovoCure?

NovoCure announced positive results from their Phase 3 LUNAR clinical trial.

Last updated: Aug 9, 2023